About Rectify Pharma
Rectify Pharma is a Healthcare company based in Cambridge (United States) founded in 2018 by Jonathan Moore. Drugs for multiple therapeutic purposes are manufactured. Rectify Pharma has raised $100 million across 2 funding rounds from investors including HHS, Atlas Venture and Omega Funds. Its chief executive, as recorded, is Rajesh Devraj. Rectify Pharma offers products and services including PFM Platform and RTY-694. Its focus areas include Diversified Pharmaceuticals.
Company details
Rectify Pharma was established in 2018 in Cambridge, United States. Operations are centered in the pharmaceutical sector, where drugs for various therapeutic areas are produced. The company is led by founder Jonathan Moore and CEO Rajesh Devraj. Focus is placed on manufacturing processes to support multiple medical applications, with activities conducted from the U.S. base.
- Headquarters Cambridge, United States
- Founders Jonathan Moore
- SectorsHealthcare
- Email••••••••
- Website rectifypharma.com
- Social LinkedIn X
- Total Equity Funding$100M (USD)
in 2 rounds
- Latest Funding Round$100M (USD), Series A
Oct 2021
- InvestorsHHS
& 4 more
Products & Services of Rectify Pharma
Rectify Pharma offers a comprehensive portfolio of products and services, including PFM Platform and RTY-694.
Proprietary system for discovering therapies that rectify membrane protein dysfunction.
Oral modulator addressing cholestasis and cholangitis in hepatobiliary diseases.
Funding Insights of Rectify Pharma
Rectify Pharma has successfully raised a total of $100M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $100 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $100M
- Total Rounds 2
- Last Round Series A — $100M
- First Round $230,686
(May 2019)
- Investors Count 5
All 2 funding rounds of Rectify Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2021 | $100M | Series A | – | Omega Funds, Atlas Venture | – |
| May 2019 | $230,686 | Grant | – | – |
5 investors in total: 5 institutional.
Investors in Rectify Pharma
Rectify Pharma has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Atlas Venture and Omega Funds.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm | omegafunds.com | Boston, United States | ||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Venture capital firm focused on lifescience and healthcare sectors | forbion.com | Naarden, Netherlands | ||
Venture capital is directed toward healthcare companies by Longwood Fund. | longwoodfund.com | Boston, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Rectify Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Rectify Pharma
19 people are tracked at Rectify Pharma (7 in leadership, 10 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Jonathan Moore | Founder | Leadership |
Rajesh Devraj | CEO | Leadership |
Sachiyo Minegishi | COO | Leadership |
Eric Bell | Senior Director Translational Science | Leadership |
Todd Bosanac | Vice President, Medicinal Chemistry | Leadership |
Nathan Fuller | Vp, Chemistry | Leadership |
John Miller | VP & Head of Biology | Leadership |
Bob Copeland | Scientific Advisor | Board & advisors |
Marco Boorsma | Director | Board & advisors |
Jodie Morrison | Director | Board & advisors |
David Steinberg | Director | Board & advisors |
Jamie Williamson | Scientific Advisor | Board & advisors |
Jason Rhodes | Director | Board & advisors |
Richard Chesworth | Scientific Advisor | Board & advisors |
Richard Thompson | Scientific Advisor | Board & advisors |
Tuyen Ong | Director | Board & advisors |
Jason Campagna | Scientific Advisor | Board & advisors |
Robert Hughes | EVP, Drug Discovery & Preclinical Development | Team |
Carolyn Gilson | Executive Assistant/Office Manager | Team |
Complete people profiles for Rectify Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Rectify Pharma
3 dated milestones of Rectify Pharma across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Rectify Pharma is founded.
- Funding First funding round of $231K.
- Funding Latest funding round, Series A, of $100.0M.
Web traffic of Rectify Pharma
The website of Rectify Pharma (rectifypharma.com) receives about 2.1K visits a month.
- Monthly visits2.1K
▲ 42.6% vs previous month
Websites whose visitors overlap most with Rectify Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| forbion.com | 100% | #1,171,296 | View details |
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Rectify Pharma (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rectify Pharma
Complete news archive for Rectify Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rectify Pharma
Rectify Pharma was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Rectify Pharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Rajesh Devraj is the CEO of Rectify Pharma, as recorded in our data.
Rectify Pharma is a funded company, having raised a total of $100M across 2 funding rounds to date. The company's 1st funding round was a Grant of $230.69K, raised on May 2019.
Rectify Pharma was established in 2018 in Cambridge, United States. Operations are centered in the pharmaceutical sector, where drugs for various therapeutic areas are produced. The company is led by founder Jonathan Moore and CEO Rajesh Devraj. Focus is placed on manufacturing processes to support multiple medical applications, with activities conducted from the U.S. base.
Rectify Pharma offers PFM Platform and RTY-694.
Rectify Pharma has 5 investors. Key investors include HHS, Atlas Venture, Omega Funds, Forbion, and Longwood Fund.